TGFB1 and pulmonary fibrosis: Wu et al. (2014) showed that TanIIA treatment attenuates bleomycin-induced pulmonary fibrosis and inflammation and decreases expression of TGF-β1 via modulating angiotensin-converting enzyme 2/angiotensin-(1–7) axis in rats.